Intravenous immunoglobulin in therapy of peripheral neuropathy.
Peripheral neuropathy (PN) can be a manifestation of various neurological, infectious, metabolic, autoimmune, rheumatic, and malignant diseases. During the past decade, intravenous immunoglobulin (IVIg) has been increasingly used in the therapy of PN. Compared with other immunomodulatory therapies, IVIg has an excellent safety profile. IVIg is used today as a first-line therapy in the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Some small studies and reports of clinical cases presented in this article found benefit from IVIg in treating PN associated with diabetes, paraproteinemia, HIV, multisystem rheumatic diseases, and paraneoplastic PN. No clear recommendations can be made relating the use of IVIg in these conditions. Prospective, randomized trials are required to clarify this issue.
Gorshtein
Alexander
A
Department of Internal Medicine E, Meir Hospital, Kfar Saba, Israel.
Levy
Yair
Y
D001327:Autoimmune Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy*; D020127:Recovery of Function
D016756:Immunoglobulins, Intravenous